Across TCGA pan-cancer cohorts, AMPD1 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated AMPD1 data layer compared with 29 for mass-spec protein and 8 for mutation status.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher AMPD1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated AMPD1 expression acts as an unfavorable survival marker.
HNSC are the cancer types where AMPD1 mass-spec protein most reproducibly stratifies survival.